BridgeBio Pharma Statistics
Total Valuation
BBIO has a market cap or net worth of $15.52 billion. The enterprise value is $18.17 billion.
| Market Cap | 15.52B |
| Enterprise Value | 18.17B |
Important Dates
The last earnings date was Monday, August 10, 2026, after market close.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BBIO has 195.49 million shares outstanding. The number of shares has increased by 2.29% in one year.
| Current Share Class | 195.49M |
| Shares Outstanding | 195.49M |
| Shares Change (YoY) | +2.29% |
| Shares Change (QoQ) | +0.51% |
| Owned by Insiders (%) | 3.94% |
| Owned by Institutions (%) | 87.01% |
| Float | 167.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 21.85 |
| Forward PS | 12.14 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 25.57 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.23
| Current Ratio | 1.23 |
| Quick Ratio | 1.09 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.32 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -26.00% |
| Return on Invested Capital (ROIC) | -63.06% |
| Return on Capital Employed (ROCE) | -146.28% |
| Weighted Average Cost of Capital (WACC) | 8.80% |
| Revenue Per Employee | $710,936 |
| Profits Per Employee | -$689,796 |
| Employee Count | 1,003 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 1.12 |
Taxes
| Income Tax | -1.67M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +67.84% in the last 52 weeks. The beta is 0.98, so BBIO's price volatility has been similar to the market average.
| Beta (5Y) | 0.98 |
| 52-Week Price Change | +67.84% |
| 50-Day Moving Average | 79.44 |
| 200-Day Moving Average | 73.44 |
| Relative Strength Index (RSI) | 43.86 |
| Average Volume (20 Days) | 2,170,184 |
Short Selling Information
The latest short interest is 23.34 million, so 11.94% of the outstanding shares have been sold short.
| Short Interest | 23.34M |
| Short Previous Month | 25.75M |
| Short % of Shares Out | 11.94% |
| Short % of Float | 13.96% |
| Short Ratio (days to cover) | 6.98 |
Income Statement
In the last 12 months, BBIO had revenue of $713.07 million and -$691.87 million in losses. Loss per share was -$3.57.
| Revenue | 713.07M |
| Gross Profit | 673.41M |
| Operating Income | -477.82M |
| Pretax Income | -703.68M |
| Net Income | -691.87M |
| EBITDA | -472.75M |
| EBIT | -477.82M |
| Loss Per Share | -$3.57 |
Balance Sheet
The company has $720.16 million in cash and $3.37 billion in debt, with a net cash position of -$2.65 billion or -$13.57 per share.
| Cash & Cash Equivalents | 720.16M |
| Total Debt | 3.37B |
| Net Cash | -2.65B |
| Net Cash Per Share | -$13.57 |
| Equity (Book Value) | -2.51B |
| Book Value Per Share | -12.88 |
| Working Capital | 202.49M |
Cash Flow
In the last 12 months, operating cash flow was -$434.37 million and capital expenditures -$1.02 million, giving a free cash flow of -$435.39 million.
| Operating Cash Flow | -434.37M |
| Capital Expenditures | -1.02M |
| Depreciation & Amortization | 5.07M |
| Net Borrowing | 601.42M |
| Free Cash Flow | -435.39M |
| FCF Per Share | -$2.23 |
Margins
Gross margin is 94.44%, with operating and profit margins of -67.01% and -97.03%.
| Gross Margin | 94.44% |
| Operating Margin | -67.01% |
| Pretax Margin | -98.68% |
| Profit Margin | -97.03% |
| EBITDA Margin | -66.30% |
| EBIT Margin | -67.01% |
| FCF Margin | n/a |
Dividends & Yields
BBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.29% |
| Shareholder Yield | -2.29% |
| Earnings Yield | -4.44% |
| FCF Yield | -2.79% |
Analyst Forecast
The average price target for BBIO is $108.43, which is 36.61% higher than the current price. The consensus rating is "Buy".
| Price Target | $108.43 |
| Price Target Difference | 36.61% |
| Analyst Consensus | Buy |
| Analyst Count | 22 |
| Revenue Growth Forecast (3Y) | 72.23% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BBIO has an Altman Z-Score of -3.27 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.27 |
| Piotroski F-Score | 2 |